Keywords : Renal cell carcinoma, high blood pressure, cancer, hypertension, kidney disease, obesity
Avastin (Renal Cell Carcinoma) – Analysis and Forecasts to 2022 Summary GlobalData’s pharmaceuticals report, “Avastin (Renal Cell Carcinoma) – Analysis and Forecasts to 2022” provides Avastin sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
Avastin (Renal Cell Carcinoma) – Analysis and Forecasts to 2022
Summary
GlobalData’s pharmaceuticals report, “Avastin (Renal Cell Carcinoma) – Analysis and Forecasts to 2022” provides Avastin sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2022). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US and EU5
- Analysis and review of Avastin including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Avastin including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2012-2022 for Avastin in the US and EU5
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2012-2022 for all seven major markets
Pathology Industry in Japan
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 RCC 5
2.1.1 Types of Renal Cell Carcinoma 5
2.2 RCC Market 6
2.3 Epidemiology 6
2.4 Pathophysiology 9
2.5 Etiology 9
2.5.1 Cigarette Smoking 9
2.5.2 Obesity 10
2.5.3 Acquired Cystic Disease 10
2.5.4 Hypertension 10
2.5.5 Family History of Kidney Cancer 10
2.5.6 High Blood Pressure 10
2.5.7 Usage of Certain Medicines 10
2.5.8 Advanced Kidney Disease 10
2.5.9 Gender and Race 10
2.5.10 Genetic and Hereditary Risk Factors 11
2.5.11 Symptoms 11
2.5.12 Diagnosis 11
2.6 GlobalData Pipeline Report Guidance 14
3 RCC Disease: Market Characterization 15
3.1 RCC Disease Market 15
3.2 RCC Disease Market Forecasts and CAGR 15
3.3 Drivers for the RCC Disease Market 15
3.3.1 High Incidence 16
3.3.2 High Prevalence 17
3.3.3 Emergence of Targeted Therapies 17
3.3.4 Large Unmet Need 17
3.4 Tumor-Node-Metastases (TNM) Classification of RCC 18
3.4.1 Staging 18
3.4.2 Grading 21
3.4.3 Prognosis 21
3.5 Treatment Options in RCC 22
3.5.1 Surgery 22
3.5.2 Radiation therapy 23
3.5.3 Chemotherapy 23
3.5.4 Targeted Therapies 23
3.5.5 Tyrosine Kinase Inhibitors 25
3.5.6 Mammalian Target of Rapamycin (mTOR) Inhibitor 25
3.5.7 Vascular Endothelial Growth Factor (VEGF) Inhibitor 26
3.5.8 Treatment by Stage 26
3.6 Classification of Patients with RCC 29
4 Avastin (bevacizumab) 30
4.1 Introduction 30
4.2 Mechanism of Action 30
4.3 Clinical Studies 30
4.4 Approval History of Avastin 31
4.5 Factors Affecting Sales of Avastin 31
4.5.1 High Efficacy 31
4.5.2 Rejection in the UK 31
4.5.3 Lack of Approval in Japan 31
4.5.4 Increasing Competition 31
4.6 Drug Evaluation 32
4.6.1 Drug Risk Benefit Score 32
4.6.2 Intensity of Competition 32
4.7 Sales Forecasts 33
4.7.1 Target Patient Pool of Avastin 33
4.7.2 Dosing 33
4.7.3 Market Penetration 34
4.7.4 Annual Cost of Therapy 34
4.7.5 Sales Projections of Avastin 35
5 RCC Market: Appendix 43
5.1 Market Definitions 43
5.2 Abberiviations 43
5.3 Research Methodology 43
5.3.1 Coverage 43
5.3.2 Secondary Research 43
5.3.3 Forecasting 44
5.3.4 Number of Patients Approved to Take the Drug 44
5.3.5 Net Penetration of Drug 44
5.3.6 Net Annual Dosing 45
5.3.7 Annual Cost of Therapy 45
5.4 Drug Sales Estimates Model 45
5.5 Contact Us 45
5.6 Disclaimer 45
5.7 Sources 46
List of Tables
Table 1: RCC, Incidences and Mortality, 2008-2030 8
Table 2: RCC, TNM Classification 18
Table 3: RCC, Fuhrman grading system 21
Table 4: RCC, Treatment Guidelines 22
Table 5: Avastin, Renal Cell Carcinoma, Phase III Clinical Study Results 30
Table 6: Approval History of Avastin 31
Table 7: Avastin, Renal Cell Carcinoma, Drug Risk Benefit Score 32
Table 8: Avastin, Renal Cell Carcinoma, Global, Annual Cost of Therapy ($), 2011 34
Table 9: Avastin, Renal Cell Carcinoma, Global, Sales Estimates ($m), 2008–2022 35
Table 10: Avastin, Renal Cell Carcinoma, The US, Sales Estimates ($m), 2009–2022 36
Table 11: Avastin, Renal Cell Carcinoma, The UK, Sales Estimates ($m), 2008–2022 37
Table 12: Avastin, Renal Cell Carcinoma, France, Sales Estimates ($m), 2008–2022 38
Table 13: Avastin, Renal Cell Carcinoma, Germany, Sales Estimates ($m), 2008–2022 39
Table 14: Avastin, Renal Cell Carcinoma, Italy, Sales Estimates ($m), 2008–2022 40
Table 15: Avastin, Renal Cell Carcinoma, Spain, Sales Estimates ($m), 2008–2022 41
List of Figures
Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2010 7
Figure 2: Total number of cigarettes consumed, The US, 1976-2006 9
Figure 3: RCC, Global, Market Size Forecasts ($bn), 2010–2022 15
Figure 4: RCC, Global, Incidence (in million), 2008-2030 16
Figure 5: Oncology, Worldwide, Incidence (in million), 2008-2030 16
Figure 6: RCC, TNM Staging System 19
Figure 7: RCC, Marketed drug targets 24
Figure 8: RCC, Surgical Management 27
Figure 9: Treatment Algorithm for Metastatic Renal Cell Carcinoma 28
Figure 10: Classification of Patients with RCC 29
Figure 11: Renal Cell Carcinoma, Avastin, Drug Model Diagram 33
Figure 12: Avastin, Renal Cell Carcinoma, Global, Sales Estimates ($m), 2008–2022 35
Figure 13: Avastin, Renal Cell Carcinoma, The US, Sales Estimates ($m), 2009–2022 36
Figure 14: Avastin, Renal Cell Carcinoma, The UK, Sales Estimates ($m), 2008–2022 37
Figure 15: Avastin, Renal Cell Carcinoma, France, Sales Estimates ($m), 2008-2022 38
Figure 16: Avastin, Renal Cell Carcinoma, Germany, Sales Estimates ($m), 2008–2022 39
Figure 17: Avastin, Renal Cell Carcinoma, Italy, Sales Estimates ($m), 2008–2022 40
Figure 18: Avastin, Renal Cell Carcinoma, Spain, Sales Estimates ($m), 2008–2022 41
Figure 19: Avastin, Renal Cell Carcinoma, Global, Sales Distribution by Country (%), 2018 42
Figure 20: Patients Approved for the Drug 44
